BioVie Inc. (BIVI)
Healthcare · Biotechnology · NASDAQ · US
$1.28-8.57%Close
SELLCRISIS · day 18
$1.28-8.57%
Key stats
Short interest · FINRA settlement 2026-09-15
- Market cap
- $10M
- Beta
- 0.73
- P/E (TTM)
- -0.45
- Short % float
- 13.95%
- Days to cover
- 2.4
- SI change
- +18.2%
- 1W
- -12.93%
- 1M
- -35.03%
- vs SPY 1W
- -14.48%
- vs SPY 1M
- -36.79%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
What's Going On With BioVie Stock on Tuesday?
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Dow closes sharply lower as oil surge fuels inflation fears
BioVie advances Parkinson's Phase 3 development program with FDA engagement
BioVie Announces Update to Parkinson's Phase 3 Development Program
Dow falls as US strikes Iran, rate-hike bets jump
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie completes final patient visit in Phase 2 Long COVID trial
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
Parkinson's drug developers are betting big on inflammation
Vaalco Energy quarter sales jump, ups guidance
Apple App Store revenue ticks up despite falling downloads
Uber price target lowered by Bank of America despite higher earnings outlook
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease
